Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyzed the latest HK SFC report for aggregate short position as of Mar 14th.</li>
<li>Top short increases and decreases were tabulated for one week and four week period. </li>
<li>We highlight short changes in Trip.Com (9961 HK), ABC (1288 HK), BYD (1211 HK).</li>
</ul>


We analyzed the latest HK SFC report for aggregate short position as of Mar 14th.
Top short increases and decreases were tabulated for one week and four week period. 
We highlight short changes in Trip.Com (9961 HK), ABC (1288 HK), BYD (1211 HK).


HK Short Interest Weekly: Trip.Com, ABC, BYD

<ul>
<li>We analyzed the latest HK SFC report for aggregate short position as of Mar 7th.</li>
<li>Top short increases and decreases were tabulated for one week and four week period. </li>
<li>We highlight short changes in Trip.Com, Anta Sports, Sunac, China Tower, HKEx, CSOP HSTECH 2X ETF.</li>
</ul>


We analyzed the latest HK SFC report for aggregate short position as of Mar 7th.
Top short increases and decreases were tabulated for one week and four week period. 
We highlight short changes in Trip.Com, Anta Sports, Sunac, China Tower, HKEx, CSOP HSTECH 2X ETF.


HK Short Interest Weekly: Trip.Com, Anta Sports, Sunac, China Tower, HKEx

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

<ul>
<li>The 11th national VBP is expected to start in 2025H1. Companies such as Kelun, CSPC, Qilu Pharmaceuticals, Fosun Pharma, <a href="https://www.smartkarma.com/entities/china-resources-pharmaceutical-group" target="_blank" data-smartkarma-citation="entities:22928:1" rel="noopener">China Resources Pharmaceutical</a>, etc. are expected to be affected the most.</li>
<li>It is estimated that the entire market of PD-1/L1 x VEGF BsAb is approximately US$20-30 billion. AK112 is expected to seize about 40%-50% of the market or US$8-15 billion.</li>
<li>MIXUE's IPO debut was stellar. Conservative investors can considering taking profits as risk of share price corrections has increased. Radical investors can choose to bet on valuation exceeding Nongfu Spring.</li>
</ul>


The 11th national VBP is expected to start in 2025H1. Companies such as Kelun, CSPC, Qilu Pharmaceuticals, Fosun Pharma, China Resources Pharmaceutical, etc. are expected to be affected the most.
It is estimated that the entire market of PD-1/L1 x VEGF BsAb is approximately US$20-30 billion. AK112 is expected to seize about 40%-50% of the market or US$8-15 billion.
MIXUE's IPO debut was stellar. Conservative investors can considering taking profits as risk of share price corrections has increased. Radical investors can choose to bet on valuation exceeding Nongfu Spring.


China Healthcare Weekly (Mar.9) - 11th VBP, PD-1/VEGF BsAb Outlook, MIXUE's Stunning IPO Debut

<ul>
<li>MIXUE’s valuation should be higher than peers such as Guming and <a href="https://www.smartkarma.com/entities/sichuan-baicha-baidao-industrial-co-ltd" target="_blank" data-smartkarma-citation="entities:40029:1" rel="noopener">Baicha Baidao Industrial</a>. A comfortable valuation range is 18-20 P/E, higher than peers. So, the IPO pricing is attractive.</li>
<li>2024 full-year net profit is HK$4.8 billion.Net profit could reach HK$5.7 billion (up 19% YoY), HK$6.6 billion (up 16% YoY), HK$7.6 billion (up 15% YoY) in 2025, 2026, 2027, respectively. </li>
<li>Since Nongfu Spring’s revenue scale/net profit margin is higher than MIXUE, MIXUE’s valuation should be lower than Nongfu Spring. Investors need to be alert to the post-IPO performance growth pressure.</li>
</ul>


MIXUE’s valuation should be higher than peers such as Guming and Baicha Baidao Industrial. A comfortable valuation range is 18-20 P/E, higher than peers. So, the IPO pricing is attractive.
2024 full-year net profit is HK$4.8 billion.Net profit could reach HK$5.7 billion (up 19% YoY), HK$6.6 billion (up 16% YoY), HK$7.6 billion (up 15% YoY) in 2025, 2026, 2027, respectively. 
Since Nongfu Spring’s revenue scale/net profit margin is higher than MIXUE, MIXUE’s valuation should be lower than Nongfu Spring. Investors need to be alert to the post-IPO performance growth pressure.


Pre-IPO MIXUE Group (2097.HK) - The IPO Is Attractively Priced

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

<ul>
<li>
<a href="https://www.smartkarma.com/entities/mixue-group" target="_blank" data-smartkarma-citation="entities:40623:1" rel="noopener">Mixue Group (2097 HK)</a> raised around US$450m in its Hong Kong IPO.</li>
<li>MIXUE Group (MIXUE) is a freshly-made drinks company providing affordable products to consumers, including freshly-made fruit drinks, tea, ice cream and coffee, typically priced at around one USD per item.</li>
<li>We have covered various aspects of the deal in our previous notes. In this note, we will talk about the trading dynamics.</li>
</ul>



Mixue Group (2097 HK) raised around US$450m in its Hong Kong IPO.
MIXUE Group (MIXUE) is a freshly-made drinks company providing affordable products to consumers, including freshly-made fruit drinks, tea, ice cream and coffee, typically priced at around one USD per item.
We have covered various aspects of the deal in our previous notes. In this note, we will talk about the trading dynamics.


MIXUE IPO Trading - Strong Demand, Set to Break the Tea Chain Jinx

China

Nongfu Spring Co. Ltd. supplies soft drinks. The Company develops, produces, and sells bottled mineral water, fruit juice, sports drinks, and tea drinks. Nongfu Spring also offers barreled mineral water door-to-door services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Nongfu Spring (9633 HK)

HK Short Interest Weekly: Trip.Com, ABC, BYD

We analyzed the latest HK SFC report for aggregate short position as of Mar 14th and highlight short interest changes in Trip.Com (9961 HK), ABC...

Ke Yan, CFA, FRM

HK Short Interest Weekly: Trip.Com, Anta Sports, Sunac, China Tower, HKEx

We analyzed the latest HK SFC report for aggregate short position as of Mar 7th and highlight short interest changes in Trip.Com, Anta Sports,...

Ke Yan, CFA, FRM

China Healthcare Weekly (Mar.9) - 11th VBP, PD-1/VEGF BsAb Outlook, MIXUE's Stunning IPO Debut

The 11th national VBP in 2025H1 will impact big pharma companies. AK112 would seize 40%-50% of the PD-1/VEGF BsAb market. MIXUE's IPO debut was...

Xinyao (Criss) Wang

Pre-IPO MIXUE Group (2097.HK) - The IPO Is Attractively Priced

MIXUE's IPO debut was stellar.By March 3, market value was over HK$100 billion, higher than HK$86.4-96 billion range as analyzed in insight. P/E...

Xinyao (Criss) Wang

MIXUE IPO Trading - Strong Demand, Set to Break the Tea Chain Jinx

Mixue Group (2097 HK) raised around US$450m in its Hong Kong IPO, which was well covered. In this note, we talk about the trading dynamics.

Sumeet Singh

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

HK Short Interest Weekly: Trip.Com, ABC, BYD

We analyzed the latest HK SFC report for aggregate short position as of Mar 14th and highlight short interest changes in Trip.Com (9961 HK), ABC...

Ke Yan, CFA, FRM

HK Short Interest Weekly: Trip.Com, Anta Sports, Sunac, China Tower, HKEx

We analyzed the latest HK SFC report for aggregate short position as of Mar 7th and highlight short interest changes in Trip.Com, Anta Sports,...

Ke Yan, CFA, FRM

China Healthcare Weekly (Mar.9) - 11th VBP, PD-1/VEGF BsAb Outlook, MIXUE's Stunning IPO Debut

​The 11th national VBP in 2025H1 will impact big pharma companies. AK112 would seize 40%-50% of the PD-1/VEGF BsAb market. MIXUE's IPO debut was...

Xinyao (Criss) Wang

Pre-IPO MIXUE Group (2097.HK) - The IPO Is Attractively Priced

MIXUE's IPO debut was stellar.By March 3, market value was over HK$100 billion, higher than HK$86.4-96 billion range as analyzed in insight. P/E...

Xinyao (Criss) Wang

MIXUE IPO Trading - Strong Demand, Set to Break the Tea Chain Jinx

Mixue Group (2097 HK) raised around US$450m in its Hong Kong IPO, which was well covered. In this note, we talk about the trading dynamics.

Sumeet Singh

The 11th national VBP in 2025H1 will impact big pharma companies. AK112 would seize 40%-50% of the PD-1/VEGF BsAb market. MIXUE's IPO debut was...